Last reviewed · How we verify
Zepatier plus Sofosbuvir
Zepatier (elbasvir/grazoprevir) and Sofosbuvir work together to inhibit hepatitis C virus NS5A and NS5B proteins, blocking viral replication.
Zepatier (elbasvir/grazoprevir) and Sofosbuvir work together to inhibit hepatitis C virus NS5A and NS5B proteins, blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotype 1, 4, 5, or 6.
At a glance
| Generic name | Zepatier plus Sofosbuvir |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5A, NS3/4A protease, NS5B RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Elbasvir is an NS5A inhibitor that prevents viral protein complex formation and RNA replication. Grazoprevir is an NS3/4A protease inhibitor that blocks viral polyprotein processing. Sofosbuvir is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase. Together, this combination targets multiple steps of the HCV replication cycle.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotype 1, 4, 5, or 6
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Transplanting Hepatitis C Kidneys Into Negative Kidney Recipients (PHASE1, PHASE2)
- Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication (PHASE4)
- Transplanting Hepatitis C Lungs Into Negative Lung Recipients (PHASE1, PHASE2)
- Study of Oral Treatments for Hepatitis C (PHASE4)
- Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV) (PHASE1, PHASE2)
- A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study (PHASE2)
- Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
- Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zepatier plus Sofosbuvir CI brief — competitive landscape report
- Zepatier plus Sofosbuvir updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI